Panagiotis (Takis) completed his Ph.D. in Human Genetics and Developmental Biology from the University of Connecticut Health Center, Farmington, CT in 1998. After a post-doc on Molecular & Cellular Biology at IRCM in Montreal where he studied signaling pathways and control of gene expression during early embryonic development, he joined Aurelium BioPharma as senior scientist where he led the Cell Biology-Target Validation group from 2002-2006. During the next 5 years, he managed a Genome Canada project on the functional annotation of essential alternatively spliced isoforms in cancer at the Universite de Sherbrooke, Quebec. Subsequently, he directed the functional genomics/phenotypic platform at the Laboratory for Functional Genomics in Sherbrooke, Quebec. He joined the SGC in December, 2014 where he is leading the Oncology patient-derived tumor cell screening activities.
Takis' current interests include cell-based assays and phenotypic screening, assay development and validation, HCS/HTS screens and epigenetic pathways in tumorigenesis, cell survival and proliferation.